Patient enrollment in the International CytoSorb Registry began in May 2015. This independent, multi-national real-life registry is being conducted by the center of clinical studies, University of Jena, Germany, under the leadership of the internationally renowned sepsis researcher Professor Frank Brunkhorst and will systematically examine the clinical effects and the safety of CytoSorb therapy under “real-life” routine clinical conditions.
CytoSorbents is thus the first medical technology company to support the market introduction of a new, device-based therapy with a registry at such a high level by an independent scientific institution. The registry will enable the systematic review of the clinical effects and the safety of CytoSorb and thus contribute significantly to the expansion of knowledge about CytoSorb therapy.
All clinical CytoSorb applications can be included in the registry regardless of the indication. Data are collected only in the context of the clinical routine, so that no additional register-related examinations or procedures are required.